| Literature DB >> 20195474 |
An T T Vo1, Engeline van Duijkeren, Wim Gaastra, Ad C Fluit.
Abstract
BACKGROUND: The objective was to investigate the phenotypic and genotypic resistance and the horizontal transfer of resistance determinants from Salmonella isolates from humans and animals in Vietnam. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2010 PMID: 20195474 PMCID: PMC2829082 DOI: 10.1371/journal.pone.0009440
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Number of resistant Salmonella isolates belonging to different serovars isolated from humans, cattle, pigs and poultry in Vietnam by an agar diffusion method*.
| Sources/serovars | A | Ac | Ce | Cf | S | G | K | C | Na | No | Ci | T | Su | Tp | Co | MDR isolates N (%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| Typhimurium (21) | 14 | 2 | 1 | 14 | 11 | 10 | 6 | 11 | 2 | 2 | 15 | 15 | 12 | |||
| Enteritidis (7) | 4 | 4 | 4 | 4 | ||||||||||||
| Emek (2) | 2 | 2 | 2 | 2 | ||||||||||||
| Others (26) | 6 | 1 | 5 | 3 | 1 | 5 | 8 | 11 | 7 | 4 | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| Anatum (15) | 12 | 1 | 2 | 1 | 9 | 14 | 2 | 2 | ||||||||
| Typhimurium (3) | 3 | 1 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 3 | 2 | ||||
| Others (45) | 3 | 1 | 1 | 2 | 2 | |||||||||||
|
|
|
|
|
|
|
|
|
|
|
| ||||||
| Anatum (29) | 13 | 3 | 2 | 4 | 24 | 2 | 1 | |||||||||
| Typhimurium (23) | 18 | 18 | 18 | 18 | 2 | 18 | 18 | 18 | ||||||||
| Derby (13) | 2 | 2 | 2 | 2 | 1 | 2 | 13 | 2 | 2 | |||||||
| Others (46) | 2 | 2 | 1 | 3 | 14 | 4 | 3 | |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| Emek (26) | 1 | 1 | 1 | 2 | 28 | 26 | 1 | 28 | 28 | |||||||
| Blockley (14) | 14 | 14 | 1 | 18 | 14 | 1 | 1 | |||||||||
| Albany (3) | 3 | 1 | 3 | 3 | 2 | 3 | 3 | 1 | ||||||||
| Others (24) | 5 | 1 | 2 | 8 | 2 | 7 | 13 | 8 | 3 | |||||||
| TOTAL (267) | 86 | 6 | 6 | 77 | 38 | 48 | 58 | 91 | 3 | 3 | 148 | 101 | 81 | 1 | 125 (42) | |
| % resistant | 29 | 2.0 | 2 | 0 | 26 | 13 | 16 | 20 | 31 | 1 | 1.0 | 50 | 34 | 27 | 0.3 | |
| % intermediate | 1 | 8 | 2 | 0 | 19 | 0 | 0.3 | 5 | 8 | 0 | 0.6 | 9 | 0 | 0 | 0 | |
| % susceptible | 70 | 90 | 96 | 100 | 55 | 87 | 83 | 75 | 61 | 99 | 98.4 | 41 | 66 | 73 | 99.7 |
Abbreviations used: N, number of the isolates tested A, ampicillin (10µg); Ac, amoxicillin/clavulanic acid (30/15µg); Ce, cephalothin (30µg); Cf, ceftazidime (30µg); S, streptomycin (10µg); G, gentamicin (10µg); K, kanamycin (30µg); C, chloramphenicol (30µg), Na, nalidixic acid (30µg); No, norfloxacin (10µg); Ci, ciprofloxacin (5µg); T, tetracycline (30µg); Su, sulphonamide (300µg); Tp, trimethoprim (5µg), Co, colistin (10µg); MDR, multidrug-resistant.
The number of isolates resistant to a particular antimicrobial agent is given below each antimicrobial.
The percentage of the total number of isolates resistant, intermediate resistant or susceptible for a particular antimicrobial is indicated in the last three rows below each antimicrobial.
Characterization of class 1 integrons of Salmonella isolates from human and animal origin in Vietnam.
| IP | Size in bp (isolate ID) | RE | Fragments (bp) | RE 2 | Fragments (bp) | Gene cassette | Accession number |
| I | 1010 (V237) |
| 561; 449 |
| 411; 246; 138; 73; 61; 57; 24 |
| DQ238100 |
| 1197 |
| 703; 351; 143 |
| 826; 371 |
| DQ238099 | |
| II | 1242 (V84) |
| DQ238102 | ||||
| 1198 |
| DQ238101 | |||||
| V | 1010 (V171) |
| 561; 449 |
| 411; 246; 138; 73; 61; 57; 24 |
| DQ238098 |
| X | - | ||||||
| XI | 1242 (V14) | Hinc | 656; 490; 96 |
| 762; 480 |
| DQ238097 |
| XII | 1914 (V80) | Hinc | 1303; 611 | Hpa | 538; 464; 246; 196; 138; 116; 73; 57; 24 |
| DQ238105 |
| XIII | 1700 (V57) |
| |||||
| 1914 |
| ||||||
| 2010 |
| DQ861642 | |||||
| XIV | 1914 (V58) |
| |||||
| 2010 |
| ||||||
| XV | 627 (V48) | Bcl | 480; 147 | Nci | 351; 151; 125 |
| DQ284538 |
integron profile nomenclature followed that from a previous study [41]. Profiles (XI–XV) are designated in this study.
RE: restriction endonuclease.
- no product obtained in CS-PCR or inverted PCR.
Antimicrobial resistance characteristics of MDR Salmonella isolates from human and animal origin in Vietnam.
| Multidrug-resistance patterns | Serovars (animal/human isolates) | IP types | Conjugation | SGI 1 | ||
|
|
| Type | Excision | |||
| SSu | Derby (2/0) | V(2) | - | nt | SGI1-C | nt |
| ATNa | Anatum (13/0) | - | nt | nt | nt | nt |
| CSSu | Agona (1/0) | X (1) | + (1) | - | - | nt |
| STSu | London (3/0) | - | nt | nt | nt | nt |
| ACTNa | Anatum (1/0) | - | nt | nt | nt | nt |
| ASSuG | Kedougou (0/1) | XV (1) | - | nt | - | nt |
| ASTSu | Enteritidis (0/4) | - | nt | nt | nt | nt |
| CSuTpNa | Emek (23/1) | XI (24) | - | nt | SGI1-J3 | - |
| CTSuTp | Panama (1/0) | - | nt | nt | nt | nt |
| STKNa | Blockley (13/0) | - | nt | nt | nt | nt |
| STSuNa | Tm pt 507 (0/1), Hadar (0/1) | - | nt | nt | nt | nt |
| ACSuTpNa | Albany (1/0) | II (1) | - | nt | SGI1-F | - |
| ACTSSu | Tm pt 506 (0/1) | I (1) | - | nt | SGI1 | + |
| ACTSuTp | Panama (1/1) | X (2) | - | nt | - | nt |
| ATSuTpNa | Anatum (1/0) | X (1) | - | nt | - | nt |
| CSSuTpNa | Emek (0/1) | XI (1) | - | nt | SGI1-J3 | - |
| CSuTpGNa | Emek (2/0) | XI (2) | - | nt | - | nt |
| CSTKNa | Blockley (0/1) | - | nt | nt | nt | |
| CSTSuTp | Anatum (1/0) | XII (1) | + (1) | nt | - | nt |
| ACSTSuG | Kedougou (0/1) | X (1) | - | nt | - | nt |
| ACSTSuNa | Tm RDNC (0/1), Tm pt 506 (1/0) | I (2) | - | nt | SGI1 | + |
| ASTSuGNa | Tm RDNC (0/1) | I (1) | - | nt | SGÍ1 | + |
| ASTSuTpG | Tm 90 (4/0) | XII (4) | + (1) | + (1) | - | nt |
| ASTSuTpNa | Schwarzengrund (1/0) | XII (1) | - | nt | - | nt |
| ACSTSuTpNa | Albany (1/1) | II (2) | - | nt | SGI1-F | - |
| ATSuTpAcCeNa | Schwarzengrund (1/0) | XII (1) | - | nt | - | nt |
| ACSTSuTpNa | Tallahassee (2/0) | II (2) | - | nt | SGI1-F | - |
| CSTSuTpKNa | Blockley (1/0) | - | nt | nt | nt | nt |
| ASTSuTpGK | Tm pt 90 (8/6), Tm pt 507 (2/0), Tm RDNC (1/0), Tm pt 510 (1/0) | XII (18) | + (10) | + (6) | - | nt |
| ASTSuTpGNa | S. | XII (1) | - | nt | - | nt |
| ASTSuTpGNa | Tm UT (1/0) | XII (1) | + (1) | + (1) | - | nt |
| ACSTSuTpCeNa | Anatum (1/0) | V (1) | - | nt | - | nt |
| ACTSuTpAcCeNa | Emek (1/0) | XI (1) | - | nt | SGI1-J3 | - |
| ACSTSuTpCoNa | Albany (1/0) | II (1) | - | nt | SGI1-F | - |
| ASTSuTpGKNa | Tm 90 (1/1) | XII (2) | + (1) | + (1) | - | nt |
| ACSTSuTpGK | Derby (1/0) | XII (1) | - | nt | - | nt |
| ACSTSuTpGK | Tm 90 (2/0) | XII (2) | + (1) | + (1) | - | nt |
| ACSTSuTpGNa | Tm 90 (1/0) | - | nt | nt | nt | nt |
| ASTSuTpKGNa | Tm 90 (1/0), Tm RDNC (1/0) | - | nt | nt | nt | nt |
| ACSTSuTpAcGKNaNoCi | Tm 507 (0/1), Tm UT (0/1) | XIV (2) | + (1) | - | - | nt |
| ACSTSuTpAcCeGKNaNoCi | Tm UT (0/1) | XIII (1) | - | nt | - | nt |
Abbreviations used: A, ampicillin; C, chloramphenicol; S, streptomycin; T, tetracycline; Su, sulfonamides; Tp, trimethoprim, Ac, amoxicillin; Ce, cephalothin; G, gentamicin; K, kanamycin; Na, nalidixic acid; No, norfloxacin; Ci, ciprofloxacin; Co, colistin.
Tm, Typhimurium; RDNC, reaction does not conform to any recognized phage types; UT, untypeable phage; Ec, E. coli as the recipient; SE, S. Enteritidis as the recipient; QRDR, quinolone resistance determining region.
- not found; nt, not tested.
number in brackets: number of isolate(s).